• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Chemotherapy Induced Neutropenia - Pipeline Review, H2 2012 Product Image

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2012

  • ID: 2366378
  • December 2012
  • 87 Pages
  • Global Markets Direct

FEATURED COMPANIES

  • Eurofarma
  • LTT Bio-Pharma Co., Ltd.
  • Maxygen, Inc.
  • Med Discovery SA
  • Pfenex Inc.
  • Sandoz Inc.
  • MORE

Chemotherapy Induced Neutropenia – Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Chemotherapy Induced Neutropenia - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Chemotherapy Induced Neutropenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Neutropenia. Chemotherapy Induced Neutropenia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chemotherapy Induced Neutropenia.
- A review of the Chemotherapy Induced READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Eurofarma
  • LTT Bio-Pharma Co., Ltd.
  • Maxygen, Inc.
  • Med Discovery SA
  • Pfenex Inc.
  • Sandoz Inc.
  • MORE

2
List of Tables 6
List of Figures 7
Introduction 8
REPORT COVERAGE 8
Chemotherapy Induced Neutropenia Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Chemotherapy Induced Neutropenia 10
Chemotherapy Induced Neutropenia Therapeutics under Development by Companies 12
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Chemotherapy Induced Neutropenia Therapeutics – Products under Development by Companies 19
Companies Involved in Chemotherapy Induced Neutropenia Therapeutics Development 21
Kyowa Hakko Kirin Co., Ltd. 21
Dong-A Pharmaceutical Co., Ltd. 22
Maxygen, Inc. 23
Teva Pharmaceutical Industries Limited 24
Sandoz Inc. 25
Zosano Pharma, Inc. 26
LTT Bio-Pharma Co., Ltd. 27
Cellerant Therapeutics, Inc. 28
Med Discovery SA 29
Synageva BioPharma Corp. 30
Phage Biotechnology Corporation 31
Inimex Pharmaceuticals, Inc. 32
Bolder Biotechnology, Inc. 33
Welichem Biotech Inc. 34
USV Limited. 35
Pfenex Inc. 36
Eurofarma 37
Chemotherapy Induced Neutropenia – Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
MAXY-G34 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MDPK-67b - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Slow-Release G-CSF - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Pegylted GCSF - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
filgrastim - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
balugrastim - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
IMX-942 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
CLT-008 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
filgrastim - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
pegfilgrastim - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
pegfilgrastim - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
lipegfilgrastim - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
WBI-2100 + [cisplatin] - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
WBI-2100 + [gemcitabine hydrochloride] - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
WBI-2100 + [dacarbazine] - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
WBI-2100 + [paclitaxel] - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
TXA127 + Erythropoietin - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
filgrastim - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
BBT-015 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
BBT-018 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
IRX-4310 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
pegfilgrastim - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
filgrastim - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
filgrastim - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
filgrastim - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
F-627 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
F-627 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
filgrastim Biosimilar - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
pegfilgrastim Biosimilar - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Chemotherapy Induced Neutropenia Therapeutics – Drug Profile Updates 75
Chemotherapy Induced Neutropenia Therapeutics – Discontinued Products 79
Chemotherapy Induced Neutropenia Therapeutics - Dormant Products 80
Chemotherapy Induced Neutropenia – Product Development Milestones 81
Featured News & Press Releases 81
Jun 29, 2012: Teva Pharma Provides Clinical Update On Balugrastim At MASCC/ISOO 2012 International Symposium On Supportive Care In Cancer 81
Jun 29, 2012: Teva Pharma Provides Clinical Update On Lipegfilgrastim At MASCC/ISOO 2012 International Symposium On Supportive Care In Cancer 81
Oct 10, 2011: Maxygen Announces Final Rejection Of All Claims Of Amgen ‘804 Patent In Inter Partes Reexamination Proceeding 82
May 31, 2011: Teva Announces Data On Granulocyte Colony Stimulating Factor Compounds For Prevention Of Chemotherapy-Induced Neutropenia In Breast Cancer Patients 82
May 31, 2011: Teva To Present Phase II Data Of Granulocyte Colony Stimulating Factor XM22 At ASCO 82
Mar 24, 2011: Telik Announces Preclinical Presentation At 102nd Annual Meeting Of American Association For Cancer Research 83
Mar 22, 2011: Cellerant Initiates Phase I/II Clinical Trial Of CLT-008 For Chemotherapy Induced Neutropenia In Acute Leukemia Patients 83
Nov 03, 2010: Bolder BioTechnology Announces $1.2 Million In Qualifying Therapeutic Discovery Project Grants 84
Dec 01, 2009: Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia 84
May 08, 2002: Amgen to Acquire Filgrastim and Pegfilgrastim in Europe from Roche 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 87
Disclaimer 87

List of Tables
Number of Products Under Development for Chemotherapy Induced Neutropenia, H2 2012 10
Products under Development for Chemotherapy Induced Neutropenia – Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Development by Companies, H2 2012 (Contd..1) 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Development by Companies, H2 2012 (Contd..1) 20
Kyowa Hakko Kirin Co., Ltd., H2 2012 21
Dong-A Pharmaceutical Co., Ltd., H2 2012 22
Maxygen, Inc., H2 2012 23
Teva Pharmaceutical Industries Limited, H2 2012 24
Sandoz Inc., H2 2012 25
Zosano Pharma, Inc., H2 2012 26
LTT Bio-Pharma Co., Ltd., H2 2012 27
Cellerant Therapeutics, Inc., H2 2012 28
Med Discovery SA, H2 2012 29
Synageva BioPharma Corp., H2 2012 30
Phage Biotechnology Corporation, H2 2012 31
Inimex Pharmaceuticals, Inc., H2 2012 32
Bolder Biotechnology, Inc., H2 2012 33
Welichem Biotech Inc., H2 2012 34
USV Limited., H2 2012 35
Pfenex Inc., H2 2012 36
Eurofarma, H2 2012 37
Assessment by Monotherapy Products, H2 2012 38
Assessment by Combination Products, H2 2012 39
Assessment by Stage and Route of Administration, H2 2012 41
Assessment by Stage and Molecule Type, H2 2012 43
Chemotherapy Induced Neutropenia Therapeutics – Drug Profile Updates 75
Chemotherapy Induced Neutropenia Therapeutics – Discontinued Products 79
Chemotherapy Induced Neutropenia Therapeutics – Dormant Products 80

List of Figures
Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2012 10
Products under Development for Chemotherapy Induced Neutropenia – Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Discovery and Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 38
Assessment by Combination Products, H2 2012 39
Assessment by Route of Administration, H2 2012 40
Assessment by Stage and Route of Administration, H2 2012 41
Assessment by Molecule Type, H2 2012 42
Assessment by Stage and Molecule Type, H2 2012 43

Note: Product cover images may vary from those shown

- Kyowa Hakko Kirin Co., Ltd.
- Dong-A Pharmaceutical Co., Ltd.
- Maxygen, Inc.
- Teva Pharmaceutical Industries Limited
- Sandoz Inc.
- Zosano Pharma, Inc.
- LTT Bio-Pharma Co., Ltd.
- Cellerant Therapeutics, Inc.
- Med Discovery SA
- Synageva BioPharma Corp.
- Phage Biotechnology Corporation
- Inimex Pharmaceuticals, Inc.
- Bolder Biotechnology, Inc.
- Welichem Biotech Inc.
- USV Limited.
- Pfenex Inc.
- Eurofarma

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos